scholarly article | Q13442814 |
P356 | DOI | 10.1007/S005200050184 |
P698 | PubMed publication ID | 9695210 |
P2093 | author name string | H J Senn | |
U Hess | |||
C Böhme | |||
K Rey | |||
P433 | issue | 4 | |
P921 | main subject | amikacin | Q408529 |
ceftazidime | Q808845 | ||
piperacillin/tazobactam | Q7197337 | ||
P304 | page(s) | 402-409 | |
P577 | publication date | 1998-07-01 | |
P1433 | published in | Supportive Care in Cancer | Q15766919 |
P1476 | title | Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients | |
P478 | volume | 6 |
Q45305512 | A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies |
Q90284827 | A Randomized, Open-Labeled, Prospective Controlled Study to Assess the Efficacy of Frontline Empirical Intravenous Piperacillin/Tazobactam Monotherapy in Comparison with Ceftazidime Plus Amikacin for Febrile Neutropenia in Pediatric Oncology Patient |
Q34180913 | Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation |
Q24201767 | Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia |
Q24248048 | Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia |
Q33809969 | Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer |
Q44655203 | Comparative in vitro activity of piperacillin, piperacillin–sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients |
Q40601273 | Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996) |
Q34305094 | Infections following hematopoietic stem cell transplantation |
Q40585149 | Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis |
Q43890461 | Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections |
Q40177437 | Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey |
Q40561453 | Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. |
Q40489194 | Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial |
Q34458678 | Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections |
Q33649676 | Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections |
Q73829631 | [Impact of oral prophylaxis with quinolones on microbial agents isolated from blood cultures during febrile episodes in hematologic patients] |